Gefapixant is a P2X3 antagonist that was recently studied in two phase 3 randomized controlled trials, COUGH-1 and COUGH-2, and is currently under regulatory review in Europe. In this interview, we were delighted to speak with Elena Kum (McMaster University, Hamilton, ON, Canada) around the aims, methodology and findings from her dose-response meta-analysis of gefapixant.
The abstract ‘Efficacy and safety of gefapixant for treatment of refractory or unexplained chronic cough: a systematic review and dose-response meta-analysis.‘ was presented at ERS 2023, 9 – 13 September 2023.
Questions
- What is the mechanism of action of gefapixant? (0:06)
- What clinical trial data already supports gefapixant for the treatment of refractory or unexplained chronic cough? (0:42)
- What were the aims and methodology of your systematic review and dose-response meta-analysis? (1:28)
- What were the findings and how will they impact the regulatory applications for gefapixant? (2:33)
- What will be the next steps towards realising the potential of gefapixant? (4:59)
Disclosures: Elena Kum discloses receiving honoraria from Respiplus.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS Annual Meeting.
Click here for more content on chronic cough and here for the full published article.
